Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today ...
Vancouver, B.C., tissue ‘bioprinting’ company inks $75M deal with Novo Nordisk for diabetes, obesity
An Aspect Biosystem scientist at work on a company bioprinter. (Aspect Photo) Vancouver, B.C.-based biotech company Aspect Biosystems inked a partnership worth potentially more than $2.6 billion with ...
Aspect Biosystems and big pharma giant Novo Nordisk announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.
Vancouver’s Aspect Biosystems Ltd., which is developing technology to 3-D print live tissue implants that can replace organ functions, is deepening a pivotal relationship with pharma giant Novo ...
Novo Nordisk A/S NVO and a privately-held biotechnology company, Aspect Biosystems, announced entering a collaboration, development, and license agreement. This will bring together Aspect’s ...
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect to ...
VANCOUVER, BC and NEW YORK, April 6, 2022 /PRNewswire/ -- Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results